Loading...
Market
Will Brenus Pharma's precision cancer vaccine receive Breakthrough Therapy designation from the FDA by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements or Brenus Pharma press releases
Story
Brenus Pharma Raises €22.2 Million ($25 Million) to Advance Cancer Vaccine Trials
Sep 19, 2024, 08:13 AM
Brenus Pharma, a French biotech company based in Lyon, has successfully raised €22.2 million ($25 million) in a Series A funding round. The funds will be used to accelerate the clinical trials of its precision cancer vaccines. The funding round was led by Angelor, a prominent investment firm. Brenus Pharma specializes in developing innovative cancer vaccines aimed at improving patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%